Cargando…

Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer

BACKGROUND: Circulating tumor cells (CTCs) are associated with worse prognosis in metastatic breast cancer (BC). We evaluated the association of metabolic, inflammatory, and tumor markers with CTCs in women with metastatic BC before commencing a new systemic therapy. METHODS: Ninety-six patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lohmann, Ana Elisa, Dowling, Ryan J O, Ennis, Marguerite, Amir, Eitan, Elser, Christine, Brezden-Masley, Christine, Vandenberg, Theodore, Lee, Elma, Fazaee, Kamran, Stambolic, Vuk, Goodwin, Pamela J, Chang, Martin C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044231/ https://www.ncbi.nlm.nih.gov/pubmed/30035251 http://dx.doi.org/10.1093/jncics/pky028

Ejemplares similares

Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study
por: Elliott, Mitchell J., et al.
Publicado: (2020)

Understanding the benefit of metformin use in cancer treatment
por: Dowling, Ryan JO, et al.
Publicado: (2011)

Metformin and Exercise in Cancer: Better Together
por: Stambolic, Vuk, et al.
Publicado: (2019)

Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis
por: Lohmann, Ana Elisa, et al.
Publicado: (2021)

Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study
por: Dowling, Ryan JO, et al.
Publicado: (2015)

Intestinal Metaplasia and the Risk of Gastric Cancer in an Immigrant Asian Population
por: Abadir, Amir, et al.
Publicado: (2012)

Redefining Heart Failure in Breast Cancer
por: Volgman, Annabelle Santos, et al.
Publicado: (2022)

Cancer and Cardiovascular Disease: The Complex Labyrinth
por: Dent, Susan, et al.
Publicado: (2015)

Lgr5 and stem/progenitor gene expression in gastric/gastroesophageal junction carcinoma – significance of potentially retained stemness
por: Yoon, Ju-Yoon, et al.
Publicado: (2020)

Autophagic Heterogeneity in Gastric Adenocarcinoma
por: Yoon, Ju-Yoon, et al.
Publicado: (2021)

Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer
por: Simmons, Christine E., et al.
Publicado: (2020)

Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm
por: Yang, Charlie, et al.
Publicado: (2023)

Histo- and immunohistochemistry-based estimation of the TCGA and ACRG molecular subtypes for gastric carcinoma and their prognostic significance: A single-institution study
por: Yoon, Ju-Yoon, et al.
Publicado: (2019)

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
por: O’Shaughnessy, Joyce, et al.
Publicado: (2020)

Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective
por: Ferrario, Cristiano, et al.
Publicado: (2022)

The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor–Positive Breast Cancer
por: Lohmann, Ana Elisa, et al.
Publicado: (2022)

A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer
por: Brezden‐Masley, Christine, et al.
Publicado: (2020)

A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer
por: Brezden-Masley, Christine, et al.
Publicado: (2020)

A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer
por: Brezden-Masley, Christine, et al.
Publicado: (2020)

The Association of Oxaliplatin-Containing Adjuvant Chemotherapy Duration with Overall and Cancer-Specific Mortality in Individuals with Stage III Colon Cancer: A Population-Based Retrospective Cohort Study
por: Sue-Chue-Lam, Colin, et al.
Publicado: (2023)

Clinicians’ Perspectives on Barriers to Discussing Infertility and Fertility Preservation With Young Women With Cancer
por: Covelli, Andrea, et al.
Publicado: (2019)

Nek family of kinases in cell cycle, checkpoint control and cancer
por: Moniz, Larissa, et al.
Publicado: (2011)

Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study
por: Moskalewicz, Alexandra, et al.
Publicado: (2022)

Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo
por: Goodwin, Pamela J, et al.
Publicado: (2021)

Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial
por: Krzyzanowska, Monika K, et al.
Publicado: (2021)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2017)

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
por: Rayson, Daniel, et al.
Publicado: (2022)

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”
por: Rayson, Daniel, et al.
Publicado: (2023)

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective
por: Henning, Jan-Willem, et al.
Publicado: (2023)

Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients
por: Paoletti, Costanza, et al.
Publicado: (2021)

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines
por: Simmons, Christine, et al.
Publicado: (2022)

HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
por: Jerzak, Katarzyna J., et al.
Publicado: (2023)

Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review
por: Al-Showbaki, Laith, et al.
Publicado: (2023)

Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer
por: Lee, Michelle C. M., et al.
Publicado: (2021)

Crown-like structures in breast adipose tissue of breast cancer patients: associations with CD68 expression, obesity, metabolic factors and prognosis
por: Chang, Martin C., et al.
Publicado: (2021)

Mammographic microcalcifications and breast cancer tumorigenesis: a radiologic-pathologic analysis
por: Naseem, Madiha, et al.
Publicado: (2015)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2018)

Randomised controlled trials of non-pharmacological interventions to improve patient-reported outcomes of colonoscopy: a scoping review
por: Sue-Chue-Lam, Colin, et al.
Publicado: (2023)

Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer
por: Gerratana, Lorenzo, et al.
Publicado: (2021)

Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer
por: Theil, Gerit, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_58oc1ndi0luahbshbsh79ojbse